
$110 USD
Tesamorelin and Ipamorelin are two peptides combined in a blend that seems to be sharing the potential to stimulate the growth hormone axis, although through different mechanisms. This combination might activate the pituitary gland, which further results in the release of endogenous growth hormone. The blend seems to be showing positive effects on mammals and primates in terms of sleep, lipid profile, mean mass, muscle tissues, cognition, and metabolic function.
Molecular Formula
Molecular Weight
Sequence
Tesamorelin is an analog of the growth hormone-releasing hormone. It binds GHRG receptors on somatotrophs in the pituitary gland. Considering that it promotes the release of GH, Tesamorelin could boost lipolysis, reduce visceral adipose tissue, and potentially improve glucose metabolism.
Ipamorelin is a GHSR antagonist as well. However, it appears to be activating GHSR in the peripheral tissues and hypothalamus, potentially causing the release of GH. Researchers suggest that since GHSR stimulates the increase of GH secretion, it can promote lipolysis, protein synthesis, and IGF-1 production.
When combined, these two compounds target different components of the GH axis. This dual action seems to positively affect and amplify the overall GH, like insulin sensitivity, lipid profile, body composition, and overall metabolic function in a laboratory setting.
Research has shown that both Tesamorelin and Ipamorelin may help manage blood sugar levels and address metabolic issues in people with Type 2 Diabetes (T2DM). Tesamorelin works by boosting the body’s own production of growth hormone, which experts believe improves how the body responds to insulin and uses glucose. On the other hand, studies on Ipamorelin suggest it may positively affect insulin sensitivity and glucose regulation. When used together, these peptides could offer combined benefits, potentially leading to lower HbA1c levels, better insulin sensitivity, and reduced abdominal fat with T2DM.
References:
Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. doi: 10.14283/jfa.2018.45. PMID: 31237318; PMCID: PMC6766405.
Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. PMID: 28617838; PMCID: PMC5472315.
https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin#section=Deprecated-CAS
Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011 Jan;96(1):150-8. doi: 10.1210/jc.2010-1587. Epub 2010 Oct 13. PMID: 20943777; PMCID: PMC3038486.
https://www.sciencedirect.com/science/article/abs/pii/S1096637401902394?via%3Dihub
Same day shipping
Place your order today and we’ll ship it out the very same day.
Free shipping
Enjoy free shipping on all orders over $200 anywhere in the USA.
Premium-grade peptides
We offer quality USA made peptides of the highest purity.
We accept secure 256-bit checkout
Disclaimer
All products on this site are for Research, Development use only.
You may also like
$100 USD
$165 USD
$120 USD
$90 USD
Get the latest updates, new products and exclusive offers.